本帖最后由 老马 于 2012-1-13 21:20 编辑 % N" X6 [) U7 {( a# a$ V a+ ?* h
9 Z( a1 _7 J" m, R( i
爱必妥和阿瓦斯丁的比较: N4 ?+ M' d& c9 G
% V2 |- R q4 C ]/ a
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/. o$ z# E2 N* F- r, f" y+ ~
( t; N$ b7 q6 A& v4 X
* R. B# J( e3 T8 z3 F khttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/$ N0 L! B% g* ]
==================================================8 K7 e- h7 o: g' A
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)! J% Y% z& F: f5 Z8 f: z
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
; f W5 c- J$ [- k. v3 zResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
: Q9 X! a3 ]- m# P7 h
|